Price Cut on Contraceptive Implants Paves Way for Wider Use in Developing World

Can we help you find something?
Advocacy & Awareness
Beyond 2020
Contraceptive Security
ECHO Study
Policy and Enabling Environment
Service Delivery & Quality
Young People
Commitment Maker
Commitment Maker
Price Cut on Contraceptive Implants Paves Way for Wider Use in Developing World
Publication Date: 11/13/2013

Implant use in Kenya has risen from zero in 1999 to almost five percent in 2008, according to USAID. A price reduction agreed this year is likely to further increase availability and use.

In February, the Gates Foundation signed a deal with pharmaceutical company Bayer for it to make Jadelle - a contraceptive implant that lasts up to five years - available to 27 million women in the world’s poorest countries over the next six years.

The implants are being sold to governments and international organisations like the United Nations Population Fund (UNFPA) for $8.50 a unit, down from $18.

“We are proud to play our role in helping to avoid almost 30 million unintended pregnancies while averting some 280,000 infant and 30,000 maternal deaths as a direct benefit of theJadelle Access Programme,” said Klaus Brill, vice president of corporate commercial relations at Bayer, at a press conference in Nairobi on Thursday.

The Gates Foundation agreed a similar partnership with Merck Sharp and Dohme, which has reduced the price of Implanon, its three-year contraceptive implant, by 50 per cent over the next six years.

Family planning services are free in government facilities across Kenya but the price reduction means the government’s budget for contraceptives will stretch further.

In Nairobi, condoms are the most popular form of contraceptive, used by 40 per cent of clients in government clinics. Injections are the second most popular, followed by pills.

There was a 52 per cent increase in demand for implants in 2012, compared to 2011, according to government statistics. Condom, coil and injection use increased by 13 per cent while that of microgynon pills and bilateral tubal litigation - a permanent form of birth control that involves blocking a woman's fallopian tubes - increased by 10 per cent.

“We are trying to promote the long acting reversible contraceptive methods,” said Moses Owino, a medical officer at Mathare North health clinic. “It’s more convenient for the mother as she doesn’t have to come [to a clinic] every time.”

Resource Type:
Bill & Melinda Gates Foundation
Thomson Reuters Foundation